Welcome to our dedicated page for Equillium news (Ticker: EQ), a resource for investors and traders seeking the latest updates and insights on Equillium stock.
Equillium, Inc. (Nasdaq: EQ) is a La Jolla, California–based clinical-stage biotechnology company that publicly describes its focus as developing novel therapies for severe autoimmune and inflammatory disorders. News about Equillium often centers on the progress of its lead candidate EQ504, an investigational aryl hydrocarbon receptor (AhR) modulator, and on corporate actions that support its development strategy.
Readers of this EQ news page can follow company announcements on clinical and preclinical plans for EQ504, including preparations for Phase 1 studies in ulcerative colitis and related gastrointestinal conditions, as well as potential applications in inflammatory lung or pulmonary diseases. Equillium’s press releases also highlight scientific and translational updates, such as key opinion leader events discussing AhR modulation, intestinal inflammation and the unmet medical need in ulcerative colitis.
In addition to pipeline news, Equillium regularly reports on financing transactions like private placements and at-the-market offerings, which it links to funding the development of EQ504 and extending its operating runway. Corporate governance and leadership updates, including changes in board composition, committee membership and senior roles, are disclosed through both SEC filings and news releases.
Another recurring topic in Equillium’s news flow is its cryptocurrency treasury reserve strategy, which the company has described as part of its broader financial and growth objectives. Updates in this area appear alongside information on cash resources, investment policy changes and strategic priorities.
Investors and observers can use this news feed to monitor Equillium’s clinical plans, scientific positioning around AhR modulation, capital-raising activities, Nasdaq listing developments and treasury strategy, all of which shape the company’s path as a clinical-stage biotech focused on immuno-inflammatory diseases.
Equillium, a clinical-stage biotechnology firm, announced that CEO Bruce Steel and CMO Krishna Polu will engage in a fireside chat at the BTIG Virtual Biotechnology Conference on August 11, 2020, at 3:30 PM ET. The discussion will focus on developing treatments for severe autoimmune disorders, including their lead candidate, itolizumab, a monoclonal antibody targeting the CD6-ALCAM pathway. Itolizumab has shown promise in various conditions and has received emergency authorization in India for managing cytokine release syndrome in COVID-19 patients. For more information, visit www.equilliumbio.com.
Equillium announced significant findings from a clinical trial conducted by Biocon in India, demonstrating that itolizumab reduced mortality rates in COVID-19 patients with moderate to severe ARDS. The India's Drug Controller General approved itolizumab for emergency use against cytokine release syndrome associated with COVID-19. Following these positive topline results, Equillium is set to launch a global randomized controlled trial under a U.S. investigational new drug application, aiming to further validate itolizumab’s efficacy.
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology firm, announced that CEO Bruce Steel and CMO Krishna Polu will present at the Jefferies Virtual Healthcare Conference on June 2, 2020, at 1:30 PM ET. This presentation will focus on Equillium's innovative efforts in treating severe autoimmune and inflammatory disorders, particularly through its product candidate itolizumab (EQ001). The live webcast can be accessed on the company’s website and will be available for replay for 30 days.
Equillium, Inc. (Nasdaq: EQ) reported its first quarter 2020 financial results, revealing a net loss of $7.8 million, equating to $(0.45) per share, which is an increase compared to a $6.0 million loss or $(0.34) per share in Q1 2019. R&D expenses rose to $4.7 million, driven by clinical trial activities, while G&A expenses slightly increased to $2.7 million. Equillium's cash and equivalents amounted to $47.7 million, down from $53.1 million at the end of 2019. The company paused some clinical trials due to the COVID-19 pandemic but expects initial data from the EQUATE trial in the second half of 2020.
Equillium (Nasdaq: EQ), a biotechnology firm, will participate in the 2020 RBC Capital Markets Virtual Global Healthcare Conference on May 20, 2020. The discussion will include CEO Bruce Steel and CMO Krishna Polu, starting at 3:05 PM ET. The event will be broadcast live, and replays will be available for 30 days. Equillium is focused on developing itolizumab, a first-in-class monoclonal antibody targeting the CD6-ALCAM pathway, aimed at treating severe autoimmune and inflammatory disorders.